Alpha Ketoglutarate

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: longevity energy muscle

Research Overview

Across the cited abstracts, α-ketoglutarate (α-KG/AKG) research is most developed in aging biology and musculoskeletal disease models, with additional mechanistic work in immunometabolism and neuroinflammation. Multiple reviews frame AKG as a pleiotropic TCA-cycle metabolite with roles beyond bioenergetics, including redox control, inflammatory signaling, nitrogen/ammonia handling, and epigenetic regulation. Preclinical studies focus heavily on age-associated phenotypes (frailty/healthspan, chronic inflammation) and tissue-specific degeneration, particularly osteoarthritis and osteoporosis, where AKG levels appear reduced in diseased or aged contexts and supplementation is tested for functional rescue.

The strongest evidence in these abstracts comes from animal and cell studies showing that AKG supplementation can improve age-related outcomes and modulate conserved cellular pathways. In mice, dietary calcium-AKG is reported to extend healthspan/lifespan and reduce systemic inflammatory cytokines, with a proposed IL-10–linked anti-inflammatory mechanism. In osteoarthritis models, AKG levels are decreased in human OA cartilage and IL-1β–treated chondrocytes, and supplementation reduces inflammatory mediators and matrix-degrading enzymes while improving extracellular matrix markers; mechanistically, benefits are linked to enhanced mitophagy and reduced ROS (blocked by a mitophagy inhibitor). In age-related osteoporosis models, AKG increases bone mass and regeneration in aged rodents and improves mesenchymal stromal/stem cell function, associated with reduced repressive histone marks (H3K9me3/H3K27me3) and increased BMP signaling/Nanog expression, supporting an epigenetic component. Broader mechanistic literature also implicates AKG-related metabolic rewiring in microglial function and amyloid clearance pathways downstream of chronic NLRP3 inhibition, reinforcing connections between AKG, mitochondrial metabolism, and immune regulation.

Key gaps are translational: despite older human studies suggesting benefits in recovery, wound healing, or muscle-related outcomes, the abstracts emphasize a lack of modern, well-controlled clinical trials testing AKG for aging or age-related diseases, and uncertainty about optimal formulation (e.g., CaAKG vs other salts), dosing, duration, and long-term safety. More research is also needed to establish causality and generalizability of proposed mechanisms (anti-inflammatory cytokine shifts, mitophagy/oxidative stress control, epigenetic remodeling) across tissues and species, to identify biomarkers of target engagement (e.g., circulating/tissue AKG levels, inflammatory panels, epigenetic marks), and to clarify interactions with major immunometabolic pathways (e.g., NLRP3 inflammasome activity) in human disease contexts such as osteoarthritis, osteoporosis, and neurodegeneration.

1. What conditions has Alpha Ketoglutarate been studied for?

  • Osteoporosis / age-related bone loss: Discussed as a “promising drug” in an osteoporosis mechanisms review, and directly tested in aged rodent models where it increased bone mass and improved bone regeneration.

  • Osteoarthritis (OA): Studied in human cartilage/chondrocytes and in an ACLT-induced age-related OA rat model; tissue levels were lower in damaged OA cartilage and in IL-1β–stimulated chondrocytes.

  • Aging / frailty / healthspan and lifespan: Tested in C57BL/6 mice using calcium alpha-ketoglutarate (CaAKG) with longitudinal healthspan measures; also referenced in worms (C. elegans) as extending lifespan via ATP synthase and TOR/mTOR-related pathways (reviewed).

  • Heart failure / pressure-overload cardiac dysfunction: Studied in mice with transverse aortic constriction (TAC) and in vitro cardiomyocyte injury models (Ang II).

  • Inflammation and immunoregulation: Covered in immunometabolism reviews as an immunoregulatory metabolite (alongside succinate, itaconate, lactate), with roles in inflammatory signaling.

  • Alzheimer’s disease (AD)–related pathways: Not as direct AKG supplementation in the provided abstract, but α-ketoglutarate generation is implicated downstream of NLRP3 inflammasome modulation, affecting microglial metabolism and Aβ clearance.

  • Muscle growth, wound healing, post-surgical recovery: Mentioned in a review as suggested by small/older human studies from the 1980s–1990s (not detailed in the abstracts).

  • Idiopathic pulmonary fibrosis (IPF) / fibroblast collagen production (mechanistic metabolism): Studied in the context of glutamine→glutamate metabolism and whether conversion to α-ketoglutarate is required for TGF-β–induced collagen production; the study found glutamate→α-KG conversion was not required for collagen production in that model.

2. Does it work in treating those conditions? Summarize the evidence.

  • Osteoarthritis (preclinical + human tissue/cell evidence):

    • Observed association: α-KG content was 31.32% lower in damaged medial cartilage vs normal lateral cartilage, and 36.85% lower in IL-1β–induced osteoarthritic chondrocytes vs control.

    • Intervention evidence: α-KG supplementation in IL-1β–injured chondrocytes reversed proliferation inhibition and reduced apoptosis, increased matrix markers (ACAN, COL2A1), and decreased catabolic/inflammatory mediators (MMP13, ADAMTS5, IL-6, TNF-α).

    • Mechanism: benefits were linked to increased mitophagy and reduced ROS; effects were blocked by Mdivi-1 (mitophagy inhibitor), supporting causality in that model.

    • In vivo: findings were verified in an ACLT-induced age-related OA rat model (details not fully enumerated in the abstract, but described as verified).

    • Limitations: No human clinical trial outcomes are provided; evidence is mechanistic, cell-based, and rodent-model based.

  • Age-related osteoporosis / bone regeneration (rodent intervention evidence):

    • Administration of αKG increased bone mass in aged mice, attenuated age-related bone loss, and accelerated bone regeneration in aged rodents.

    • Cellular mechanism: αKG improved senescence-associated phenotypes in aged bone marrow MSCs and enhanced proliferation, colony formation, migration, and osteogenic potential.

    • Epigenetic/signaling mechanism: αKG decreased repressive histone marks (H3K9me3, H3K27me3) and upregulated BMP signaling and Nanog.

    • Limitations: Strong preclinical evidence, but the abstracts do not provide randomized controlled human trials for osteoporosis treatment.

  • Aging, frailty, lifespan/healthspan (mouse intervention evidence; worm evidence referenced):

    • In C57BL/6 mice, dietary CaAKG promoted a longer, healthier life with reduced systemic inflammatory cytokines; authors propose IL-10 induction suppresses chronic inflammation, contributing to “compression of morbidity.”

    • Reviews cite C. elegans lifespan extension via ATP synthase and TOR inhibition.

    • Limitations: Translation to humans is uncertain; one review explicitly states there are no recently published human studies demonstrating AKG for aging/age-related diseases and calls for further clinical studies.

  • Heart failure / pressure overload remodeling (mouse + in vitro evidence):

    • In TAC mice, AKG supplementation inhibited hypertrophy and fibrosis and improved LV systolic dysfunction.

    • In vitro, AKG reduced Ang II–induced injury markers (β-MHC, ANP), lowered ROS, reduced apoptosis, and improved mitochondrial membrane potential.

    • Proposed mechanism: enhanced mitophagy clearing damaged mitochondria and reducing ROS.

    • Limitations: Preclinical; the abstract notes effects in HF remain unclear overall and this study is an initial exploration.

  • Alzheimer’s disease pathway (indirect evidence):

    • The AD abstract links α-ketoglutarate generation to improved microglial metabolic activity and increased Aβ clearance, but the pharmacologic intervention described is chronic NLRP3 inhibition, not AKG supplementation.

    • Conclusion: Suggestive mechanistic relevance of α-KG in AD-related immune-metabolic pathways, but not evidence that AKG supplementation treats AD.

  • Idiopathic pulmonary fibrosis (mechanistic negative finding):

    • In lung fibroblasts, glutamine→glutamate conversion was required for TGF-β–induced collagen production, but conversion of glutamate to α-ketoglutarate was not required in that model—this does not support α-KG as a necessary driver of collagen production there.

3. What health benefits does it have?

  • Anti-inflammatory effects:

    • In mice given CaAKG, benefits were associated with decreased systemic inflammatory cytokines and a proposed IL-10–mediated suppression of chronic inflammation.

    • In OA chondrocytes, α-KG reduced inflammatory mediators (IL-6, TNF-α).

    • Reviews position α-KG as an immunoregulatory metabolite with roles in inflammation control.

  • Antioxidant / oxidative stress reduction:

    • OA and TAC heart models both report reduced ROS with α-KG/AKG supplementation, linked to improved cellular outcomes.

    • A review notes AKG can directly react with hydrogen peroxide to form succinate, water, and CO2, describing a plausible chemical antioxidant mechanism (as well as metabolic support via the TCA cycle).

  • Mitochondrial quality control (mitophagy):

    • In OA chondrocytes and in pressure-overload cardiac models, α-KG/AKG promoted mitophagy, proposed to clear damaged mitochondria and reduce oxidative injury.

  • Bone and stem-cell related benefits (preclinical):

    • In aged rodents, αKG increased bone mass, reduced age-related bone loss, and accelerated bone regeneration.

    • Improved function of aged bone marrow MSCs and reduced senescence-associated phenotypes; mechanistically linked to reduced repressive histone methylation marks and increased BMP/Nanog signaling.

  • Cartilage protection in OA models (preclinical):

    • Increased extracellular matrix markers (ACAN, COL2A1) and decreased catabolic enzymes (MMP13, ADAMTS5) in OA models.

  • Potential improvements in frailty/healthspan and longevity (animal data):

    • CaAKG extended lifespan and improved healthspan metrics in mice, described as reducing frailty and compressing morbidity.

    • Reviews cite worm lifespan extension via ATP synthase and TOR inhibition.

  • Muscle and recovery-related claims (limited/older human evidence):

    • A review states older human studies suggested benefits for muscle growth, wound healing, and post-surgical recovery, but the abstracts provide no modern confirmatory trials or effect sizes.

4. Does it have any downsides or side effects?

  • Human safety data are not established in these abstracts: The provided abstracts do not report adverse event rates, tolerability, or long-term safety outcomes in contemporary human trials for aging, OA, osteoporosis, or HF.

  • Evidence gap acknowledged: One review explicitly notes that no recently published human studies demonstrate AKG for treating aging/age-related diseases, implying uncertainty about real-world benefit–risk in humans.

  • Theoretical/interpretive cautions (not directly tested here):

    • Because α-KG is central to metabolism and epigenetic regulation (e.g., histone methylation changes in MSCs), effects could be context-dependent; however, the abstracts do not document specific harms from these mechanisms.

    • In heart failure, one abstract notes circulating AKG can be elevated in HF (while also decreasing with aging), suggesting AKG biology may differ by disease state; this does not establish harm from supplementation but supports caution and need for clinical testing.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic analyses or genotype-stratified responses to alpha-ketoglutarate supplementation.

  • No direct evidence in these abstracts linking AKG response to specific human genetic variants.

  • Mechanistic hints (not pharmacogenomic proof): Several studies emphasize pathways that could, in principle, vary genetically (e.g., mitophagy regulation, inflammatory signaling such as NLRP3-related pathways, and epigenetic regulation), but no variant-specific benefit or harm is demonstrated.

References

  1. Advances in pathogenesis and therapeutic strategies for osteoporosis.
    Shasha Song, Yuanyuan Guo, Yuehua Yang, Dehao Fu (2022) - Pharmacology & therapeutics
  2. The physiological metabolite α-ketoglutarate ameliorates osteoarthritis by regulating mitophagy and oxidative stress.
    Liang Liu, Wanying Zhang, Tanghao Liu, Yangfan Tan, Cheng Chen, Jun Zhao, Huan Geng, Chi Ma (2023) - Redox biology
  3. Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice.
    Azar Asadi Shahmirzadi, Daniel Edgar, Chen-Yu Liao, Yueh-Mei Hsu, Mark Lucanic, Arash Asadi Shahmirzadi, Christopher D Wiley, Garbo Gan, Dong Eun Kim, Herbert G Kasler, Chisaka Kuehnemann, Brian Kaplowitz, Dipa Bhaumik, Rebeccah R Riley, Brian K Kennedy, Gordon J Lithgow (2020) - Cell metabolism
  4. Alpha-Ketoglutarate: Physiological Functions and Applications.
    Nan Wu, Mingyao Yang, Uma Gaur, Huailiang Xu, Yongfang Yao, Diyan Li (2016) - Biomolecules & therapeutics
  5. Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations.
    Yuan Wang, Peng Deng, Yuting Liu, Yunshu Wu, Yaqian Chen, Yuchen Guo, Shiwen Zhang, Xiaofei Zheng, Liyan Zhou, Weiqing Liu, Qiwen Li, Weimin Lin, Xingying Qi, Guomin Ou, Cunyu Wang, Quan Yuan (2020) - Nature communications
  6. Alpha-Ketoglutarate dietary supplementation to improve health in humans.
    Bibek Gyanwali, Zi Xiang Lim, Janjira Soh, Clarissa Lim, Shou Ping Guan, Jorming Goh, Andrea B Maier, Brian K Kennedy (2022) - Trends in endocrinology and metabolism: TEM
  7. NLRP3-mediated glutaminolysis controls microglial phagocytosis to promote Alzheimer's disease progression.
    Róisín M McManus, Max P Komes, Angelika Griep, Francesco Santarelli, Stephanie Schwartz, Juan Ramón Perea, Johannes C M Schlachetzki, David S Bouvier, Michelle-Amirah Khalil, Mario A Lauterbach, Lea Heinemann, Titus Schlüter, Mehran Shaban Pour, Marta Lovotti, Rainer Stahl, Fraser Duthie, Juan F Rodríguez-Alcázar, Susanne V Schmidt, Jasper Spitzer, Peri Noori, Alberto Maillo, Andreas Boettcher, Brian Herron, John McConville, David Gomez-Cabrero, Jesper Tegnér, Christopher K Glass, Karsten Hiller, Eicke Latz, Michael T Heneka (2025) - Immunity
  8. Cytokine-like Roles for Metabolites in Immunity.
    Zbigniew Zasłona, Luke A J O'Neill (2020) - Molecular cell
  9. Alpha-ketoglutarate as a potent regulator for lifespan and healthspan: Evidences and perspectives.
    Saghi Hakimi Naeini, Laleh Mavaddatiyan, Zahra Rashid Kalkhoran, Soroush Taherkhani, Mahmood Talkhabi (2023) - Experimental gerontology
  10. Alpha-ketoglutarate ameliorates pressure overload-induced chronic cardiac dysfunction in mice.
    Dongqi An, Qingchun Zeng, Peijian Zhang, Zhuang Ma, Hao Zhang, Zuheng Liu, Jiaying Li, Hao Ren, Dingli Xu (2021) - Redox biology
  11. The Antioxidative Function of Alpha-Ketoglutarate and Its Applications.
    Shaojuan Liu, Liuqin He, Kang Yao (2018) - BioMed research international
  12. Glutamine Metabolism Is Required for Collagen Protein Synthesis in Lung Fibroblasts.
    Robert B Hamanaka, Erin M O'Leary, Leah J Witt, Yufeng Tian, Gizem A Gökalp, Angelo Y Meliton, Nickolai O Dulin, Gökhan M Mutlu (2019) - American journal of respiratory cell and molecular biology
  13. The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications.
    Dingfu Xiao, Liming Zeng, Kang Yao, Xiangfeng Kong, Guoyao Wu, Yulong Yin (2016) - Amino acids
  14. Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use.
    Barbara Zdzisińska, Aleksandra Żurek, Martyna Kandefer-Szerszeń (2017) - Archivum immunologiae et therapiae experimentalis
  15. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.
    Johanna Mondesir, Christophe Willekens, Mehdi Touat, Stéphane de Botton (2016) - Journal of blood medicine
  16. Pleiotropic effects of alpha-ketoglutarate as a potential anti-ageing agent.
    Maria M Bayliak, Volodymyr I Lushchak (2021) - Ageing research reviews
  17. Sustained therapeutic effects of self-assembled hyaluronic acid nanoparticles loaded with α-Ketoglutarate in various osteoarthritis stages.
    Xinli Wang, Yufei Xue, Kaili Hao, Bo Peng, Hongli Chen, Hui Liu, Jing Wang, Jiahao Cao, Wengang Dong, Siqi Zhang, Qian Yang, Jia Li, Wei Lei, Yafei Feng (2025) - Biomaterials
  18. Glutaminolysis Promotes Collagen Translation and Stability via α-Ketoglutarate-mediated mTOR Activation and Proline Hydroxylation.
    Jing Ge, Huachun Cui, Na Xie, Sami Banerjee, Sijia Guo, Shubham Dubey, Stephen Barnes, Gang Liu (2018) - American journal of respiratory cell and molecular biology
  19. α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia.
    Scott E Millman, Almudena Chaves-Perez, Sudha Janaki-Raman, Yu-Jui Ho, John P Morris, Varun Narendra, Chi-Chao Chen, Benjamin T Jackson, Jossie J Yashinskie, Riccardo Mezzadra, Tessa I Devine, Valentin J A Barthet, Michelle Saoi, Timour Baslan, Sha Tian, Zohar Sachs, Lydia W S Finley, Justin R Cross, Scott W Lowe (2025) - Blood
  20. Psat1-generated α-ketoglutarate and glutamine promote muscle stem cell activation and regeneration.
    Veronica Ciuffoli, Xuesong Feng, Kan Jiang, Natalia Acevedo-Luna, Kyung Dae Ko, A Hong Jun Wang, Giulia Riparini, Mamduh Khateb, Brian Glancy, Stefania Dell'Orso, Vittorio Sartorelli (2024) - Genes & development


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!